Construction and validation of a nomogram for cancer specific survival of postoperative pancreatic cancer based on the SEER and China database

被引:2
作者
Peng, Wei [1 ,2 ]
Yu, Xiaopeng [3 ]
Yang, Renyi [3 ]
Nie, Sha [4 ]
Jian, Xiaolan [1 ]
Zeng, Puhua [1 ,5 ]
机构
[1] Hunan Acad Tradit Chinese Med, Affiliated Hosp, Changsha 410006, Peoples R China
[2] Hunan Univ Tradit Chinese Med, Sch Integrated Chinese & Western Med, Changsha 410006, Peoples R China
[3] Hunan Univ Chinese Med, Changsha 410208, Hunan, Peoples R China
[4] Fourth Hosp Changsha, Changsha 410006, Hunan, Peoples R China
[5] Hunan Acad Tradit Chinese Med, Canc Res Inst, Changsha, Hunan, Peoples R China
关键词
Postoperative patients with pancreatic cancer; Nomogram; Cancer specific survival; Prediction model; SEER database; GEMCITABINE; DECISION;
D O I
10.1186/s12876-024-03180-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundThe recurrence rate and mortality rate among postoperative pancreatic cancer patients remain elevated. This study aims to develop and validate the cancer-specific survival period for individuals who have undergone pancreatic cancer surgery.MethodsWe extracted eligible data from the Surveillance, Epidemiology, and End Results database and randomly divided all patients into a training cohort and an internal validation cohort. External validation was performed using a separate Chinese cohort. The nomogram was developed using significant risk factors identified through univariate and multivariate Cox proportional hazards regression. The effectiveness of the nomogram was assessed using the area under the time-dependent curve, calibration plots, and decision curve analysis. Kaplan-Meier survival curves were utilized to visualize the risk stratification of nomogram and AJCC stage.ResultsSeven variables were identified through univariate and multivariate analysis to construct the nomogram. The consistency index of the nomogram for predicting overall survival was 0.683 (95% CI: 0.675-0.690), 0.689 (95% CI: 0.677-0.701), and 0.823 (95% CI: 0.786-0.860). The AUC values for the 1- and 2-year time-ROC curves were 0.751 and 0.721 for the training cohort, 0.731 and 0.7554 for the internal validation cohort, and 0.901 and 0.830 for the external validation cohorts, respectively. Calibration plots demonstrated favorable consistency between the predictions of the nomogram and actual observations. Moreover, the decision curve analysis indicated the clinical utility of the nomogram, and the risk stratification of the nomogram effectively identified high-risk patients.ConclusionThe nomogram guides clinicians in assessing the survival period of postoperative pancreatic cancer patients, identifying high-risk groups, and devising tailored follow-up strategies.
引用
收藏
页数:10
相关论文
共 32 条
  • [1] Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors
    Arita, Junichi
    Ichida, Akihiko
    Nagata, Rihito
    Mihara, Yuichiro
    Kawaguchi, Yoshikuni
    Ishizawa, Takeaki
    Akamatsu, Nobuhisa
    Kaneko, Junichi
    Hasegawa, Kiyoshi
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (07) : 732 - 740
  • [2] Nomograms in oncology: more than meets the eye
    Balachandran, Vinod P.
    Gonen, Mithat
    Smith, J. Joshua
    DeMatteo, Ronald P.
    [J]. LANCET ONCOLOGY, 2015, 16 (04) : E173 - E180
  • [3] X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp, RL
    Dolled-Filhart, M
    Rimm, DL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7252 - 7259
  • [4] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
    Conroy, T.
    Hammel, P.
    Hebbar, M.
    Ben Abdelghani, M.
    Wei, A. C.
    Raoul, J. -L.
    Chone, L.
    Francois, E.
    Artru, P.
    Biagi, J. J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Volet, J.
    Sauvanet, A.
    Breysacher, G.
    Di Fiore, F.
    Cripps, C.
    Kavan, P.
    Texereau, P.
    Bouhier-Leporrier, K.
    Khemissa-Akouz, F.
    Legoux, J. -L.
    Juzyna, B.
    Gourgou, S.
    O'Callaghan, C. J.
    Jouffroy-Zeller, C.
    Rat, P.
    Malka, D.
    Castan, F.
    Bachet, J. -B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) : 2395 - 2406
  • [5] Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
    Deng, G. C.
    Lv, Y.
    Yan, H.
    Sun, D. C.
    Qu, T. T.
    Pan, Y. T.
    Han, Q. L.
    Dai, G. H.
    [J]. BMC CANCER, 2021, 21 (01)
  • [6] Pancreatoduodenectomy for Ductal Adenocarcinoma Implications of Positive Margin on Survival
    Fatima, Javairiah
    Schnelldorfer, Thomas
    Barton, Joshua
    Wood, Christina M.
    Wiste, Heather J.
    Smyrk, Thomas C.
    Zhang, Lizhi
    Sarr, Michael G.
    Nagorney, David M.
    Farnell, Michael B.
    [J]. ARCHIVES OF SURGERY, 2010, 145 (02) : 167 - 172
  • [7] Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan
    Fornaro, Lorenzo
    Leone, Francesco
    Vienot, Angelique
    Casadei-Gardini, Andrea
    Vivaldi, Caterina
    Lievre, Astrid
    Lombardi, Pasquale
    De Luca, Emmanuele
    Vernerey, Dewi
    Sperti, Elisa
    Musettini, Gianna
    Satolli, Maria Antonietta
    Edeline, Julien
    Spadi, Rosella
    Neuzillet, Cindy
    Falcone, Alfredo
    Pasquini, Giulia
    Clerico, Mario
    Passardi, Alessandro
    Buscaglia, Paola
    Meurisse, Aurelia
    Aglietta, Massimo
    Brac, Clemence
    Vasile, Enrico
    Montagnani, Francesco
    [J]. CLINICAL COLORECTAL CANCER, 2019, 18 (04) : E394 - E401
  • [8] Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
    Gillen, Sonja
    Schuster, Tibor
    zum Bueschenfelde, Christian Meyer
    Friess, Helmut
    Kleeff, Joerg
    [J]. PLOS MEDICINE, 2010, 7 (04)
  • [9] Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma
    Groot, Vincent P.
    Rezaee, Neda
    Wu, Wenchuan
    Cameron, John L.
    Fishman, Elliot K.
    Hruban, Ralph H.
    Weiss, Matthew J.
    Zheng, Lei
    Wolfgang, Christopher L.
    He, Jin
    [J]. ANNALS OF SURGERY, 2018, 267 (05) : 936 - 945
  • [10] Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
    Hamada, T.
    Nakai, Y.
    Yasunaga, H.
    Isayama, H.
    Matsui, H.
    Takahara, N.
    Sasaki, T.
    Takagi, K.
    Watanabe, T.
    Yagioka, H.
    Kogure, H.
    Arizumi, T.
    Yamamoto, N.
    Ito, Y.
    Hirano, K.
    Tsujino, T.
    Tada, M.
    Koike, K.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (08) : 1943 - 1949